Plant ID: NPO10367
Plant Latin Name: Gaillardia coahuilensis
Taxonomy Genus: Gaillardia
Taxonomy Family: Asteraceae
NCBI TaxonomyDB:
373158
Plant-of-the-World-Online:
n.a.
KCNA3; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
Potassium channels | KCNA3 | Voltage-gated potassium channel subunit Kv1.3 | P22001 | CHEMBL4633 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.905E-14 | 1.383E-10 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
MF | GO:0005488; binding | GO:0020037; heme binding | 5.238E-13 | 2.281E-09 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
MF | GO:0005488; binding | GO:0005506; iron ion binding | 2.044E-12 | 5.564E-09 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 2.850E-11 | 6.206E-08 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 5.332E-11 | 1.056E-07 | CYP19A1, CYP1A1, CYP1A2, CYP1B1 |
MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 2.789E-10 | 3.196E-07 | CYP19A1, CYP1A1, CYP2C19, CYP2C9 |
BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 5.826E-10 | 6.343E-07 | CYP1A2, CYP2C19, CYP2C9 |
BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 6.403E-09 | 6.062E-06 | CYP1A2, CYP2C19, CYP2C9 |
BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 5.145E-08 | 4.309E-05 | CYP1A1, CYP1A2, CYP1B1 |
CC | GO:0016020; membrane | GO:0005789; endoplasmic reticulum membrane | 7.770E-08 | 5.834E-05 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 6.752E-07 | 3.869E-04 | CYP1A1, CYP1A2 |
MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 6.752E-07 | 3.869E-04 | CYP1A2, CYP2C9 |
BP | GO:0008152; metabolic process | GO:0050665; hydrogen peroxide biosynthetic process | 3.149E-06 | 1.693E-03 | CYP1A1, CYP1A2 |
BP | GO:0008152; metabolic process | GO:0009056; catabolic process | 4.723E-06 | 2.285E-03 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 7.417E-06 | 3.106E-03 | CYP1A2, CYP2C9 |
BP | GO:0009987; cellular process | GO:0071280; cellular response to copper ion | 8.764E-06 | 3.601E-03 | CYP1A1, CYP1A2 |
MF | GO:0003824; catalytic activity | GO:0008392; arachidonic acid epoxygenase activity | 1.527E-05 | 6.046E-03 | CYP2C19, CYP2C9 |
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 2.362E-16 | 5.143E-12 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
MF | GO:0005488; binding | GO:0019825; oxygen binding | 7.896E-16 | 8.597E-12 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
CC | GO:0016020; membrane | GO:0031090; organelle membrane | 8.975E-04 | 2.246E-01 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
CC | GO:0043226; organelle | GO:0043231; intracellular membrane-bounded organelle | 1.992E-02 | 1.000E+00 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|---|
09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 2.136E-11 | 2.777E-10 | CYP2C9, CYP1A2, CYP1A1, CYP1B1, CYP2C19 |
09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 2.214E-09 | 1.439E-08 | CYP1A2, CYP1A1, CYP1B1, CYP19A1 |
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 5.669E-09 | 2.456E-08 | CYP2C9, CYP1A2, CYP1A1, CYP1B1 |
09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 2.580E-07 | 6.707E-07 | CYP1A2, CYP1A1, CYP1B1 |
09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 5.110E-07 | 1.107E-06 | CYP1A1, CYP1B1, CYP19A1 |
09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 9.556E-08 | 3.106E-07 | CYP2C9, CYP1A2, CYP2C19 |
09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 1.136E-06 | 2.110E-06 | CYP2C9, CYP1A2, CYP1A1 |
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 1.362E-06 | 2.213E-06 | CYP2C9, CYP1A2, CYP2C19 |
Unclassified | Unclassified | hsa01100 | Metabolic pathways | 1.711E-05 | 2.472E-05 | CYP2C9, CYP1A2, CYP1A1, CYP2C19, CYP19A1 |
09100 Metabolism | 09103 Lipid metabolism | hsa00590 | Arachidonic acid metabolism | 1.966E-04 | 2.556E-04 | CYP2C9, CYP2C19 |
09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 6.408E-04 | 7.574E-04 | CYP2C9, CYP2C19 |
09100 Metabolism | 09110 Biosynthesis of other secondary metabolites | hsa00232 | Caffeine metabolism | 1.749E-03 | 1.895E-03 | CYP1A2 |
ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
---|---|---|---|
C00-D49: Neoplasms | Breast cancer | C50 | CYP19A1; |
C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1; |
N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; |
C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | KCNA3; |
N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1; |
C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1; |
C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1; |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic arthritis | L40.5, M07 | KCNA3; |